1. Home
  2. PLBY vs LEXX Comparison

PLBY vs LEXX Comparison

Compare PLBY & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.76

Market Cap

232.8M

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.62

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
LEXX
Founded
1953
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.8M
14.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PLBY
LEXX
Price
$1.76
$0.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$4.00
AVG Volume (30 Days)
1.4M
405.3K
Earning Date
11-12-2025
01-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$119,510,000.00
$705,923.00
Revenue This Year
$4.97
$13.35
Revenue Next Year
$8.38
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
52.05
52 Week Low
$0.90
$0.48
52 Week High
$2.53
$2.43

Technical Indicators

Market Signals
Indicator
PLBY
LEXX
Relative Strength Index (RSI) 46.89 33.25
Support Level $1.70 $0.48
Resistance Level $1.97 $0.70
Average True Range (ATR) 0.20 0.12
MACD -0.06 -0.06
Stochastic Oscillator 7.23 15.07

Price Performance

Historical Comparison
PLBY
LEXX

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: